Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRSA - Methicillin-resistant Staphylococcus aureus -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (60)	11/1/2007 6:28:04 PM
From: caly	Respond to of 191

Cepheid announced their Q3 results this evening. They're going gangbusters. MRSA-relevant data from the release is below... biz.yahoo.com * Clinical product sales of $20.7 million, a 258 percent increase from $5.8 million in the third quarter of 2006. The increase in clinical sales was driven by market adoption of both the GeneXpert® System and the Company's menu of available tests, specifically the Xpert(TM) MRSA product that provides rapid detection of Methicillin- resistant Staphylococcus aureus (MRSA). The Company focused on GeneXpert System installations during the third quarter, and expects test sales volumes to increase as accounts become fully operational. The U.S. Food and Drug Administration cleared Cepheid's Xpert MRSA test in April 2007. As of September 30, 2007, Cepheid has installed 1,786 diagnostic GeneXpert modules in Europe and the U.S., which is an increase of 800, or 81 percent, from the second quarter of 2007. Providing unique account scalability, the GeneXpert System is presently configurable with anywhere from one to 16 modules. The new Infinity Series of GeneXpert Systems, currently in development, will extend this capability up to 72 modules. This configuration flexibility and volume capacity has been particularly attractive to large hospitals seeking on-demand test capability as they have made time-critical, active MRSA surveillance a priority.